The USC Alzheimer’s research team has identified three critical advances that distinguish this enzyme-targeting approach from previous failed anti-inflammatory strategies. First, the newly developed compounds selectively inhibit cytosolic phospholipase A2 (cPLA2), the specific enzyme driving harmful brain inflammation in susceptible populations. Second, this selective mechanism preserves essential brain functions, addressing a fundamental limitation of broad anti-inflammatory drugs that inadvertently caused cognitive impairment.
Third, this precision medicine strategy may especially benefit the approximately 25 percent of the population carrying the APOE4 gene variant, who experience disproportionate neuroinflammation and accelerated disease progression. By redirecting cPLA2 activity away from destructive inflammatory pathways while maintaining its role in normal brain repair processes, these compounds offer a biologically informed therapeutic approach. For patients and families affected by Alzheimer’s disease, particularly APOE4 carriers, this research signals meaningful progress toward disease-modifying treatments that address underlying pathological mechanisms.
Read the full article on GMJ Newsroom.
Was this article helpful?
